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Diminishing the Side Effects of Cancer Treatment by Improving Treatment Delivery
Alexander Kalin
Cancer is one of the leading causes of death in the world and is expected to become more
prevalent each year. Cancer is caused by the uncontrollable growth of cells within the
human body. This excessive growth can lead to the formation of malignant tumors, which
invade parts of the body. Currently, the most common approach to treating cancer is
surgery, chemotherapy, and radiation treatment. However, chemotherapy and radiation
can cause drastic, harmful side effects to patients because they not only affect cancer
cells, but normal proliferative cells as well. In many cases, a particular chemotherapy is
avoided because the risks of side effects greatly outweigh the effect of the drug on the
tumor. Therefore, if adverse effects are going to be eliminated and cancer treatment
optimized, tumor cells must be specifically targeted and normal cells spared. One method
of generating tumor specificity in cancer treatment that has recently gained interest and
optimism is the use of medical devices. As technology has improved, the possibilities and
applications of medical devices have become nearly limitless. In cancer treatment,
medical devices can guide their cargo, whether it is a drug or radiation, directly to tumor
sites within the patient. As a result, adverse effects should be diminished and cancer
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1Introduction
Cancer is a troubling, deadly disease that has been affecting people for centuries.
Cancer involves the uncontrollable growth of cells in the body, forming tumors (1). In
2008, cancer was a leading cause of death (13% of deaths) in the world (2). There are
over 200 types of cancer and many facts are still unknown about the disease. Treatment
options and effectiveness has significantly grown and improved over the years, especially
recently; however, one common theme among cancer treatments is the incidence of
adverse effects. Even though tumors may be eliminated after surgery or shrunk
immediately after chemotherapy, the health and well-being of patients are affected by
conditions such as nausea, hair loss, infection, anemia, nerve problems, urinary problems,
and many others (3). Furthermore, many potential cancer treatments that can have
curative implications do not even receive FDA (Food and Drug Administration) approval
because of the severity of their side effects compared to their effect on the tumor (4). The
incidence of side effects can be explained by the current, common approach of treating
cancer. Proliferating cells are targeted by small molecules, antibodies, radiation, or other
compounds, usually causing apoptosis, or cell death. However, tumor cells are not the
only proliferating cells in the body of a cancer patient. Normal, noncancerous
proliferating cells, such as blood cells, hair cells, and cells that line the digestive system,
are also unintentionally targeted by cancer treatments, leading to the adverse effects
previously mentioned. This realization highlights the importance of improving treatment
delivery so that only cancerous cells are targeted, sparing normal cells and diminishing
adverse effects. One area of research that has gained much attention bridges biology and
2engineering to generate medical devices which can be used to direct cancer treatments,
such as chemotherapy and radiation, to desired locations within patients.
With modern technology, medical devices are involved in almost every aspect of
the medical field and are responsible for saving countless lives. Medical devices have
been used for many years, including the scalpels used for the first surgeries and syringes
that delivered the first vaccines. However, medical devices only started being regulated,
similar to drugs, in the 1970s as they became more advanced and medically influential
(5). According to the FDCA (Federal Food, Drug, and Cosmetic Act), a medical device
is:
“An instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article,
including any component, part, or accessory, which is
1. Recognized in the official National Formulary or the United States
Pharmacopeia, or any supplement to them,
2. Intended for use in the diagnosis of disease or other conditions, or
in the cure, mitigation, treatment, or prevention of disease, in
man or other animals, or
3. Intended to affect the structure or any function of the body of man
or other animals, and
which does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals
and which is not dependent upon being metabolized for the
achievement of its primary intended purposes.” (5)
Therefore, medical devices include a wide variety of instruments with varying
applications that can range from operating room monitors to contact lenses to sunscreen.
The vast potential of medical devices illustrates the importance it can have in treatment
delivery. For example, rather than administer a drug or radiation alone, a medical device,
that can be injected or implanted, can be designed to deliver the treatment at particular
times and/or locations. Since the medical device is expected to provide precise delivery,
3normal cells can be avoided, diminishing side effects. Medical devices that exhibit these
properties are either practiced in the medical field or being developed and tested today (6-
10). Among these, radiation seeds, which can be delivered in specific locations, are being
used that proximally emit radiation to tumor cells (6). Balloon catheters also deliver
localized radiation to tumors, but can be used in hard-to-treat regions such as the brain
(7). Nanoparticles and carbon nanotubes that encase or carry a desired therapeutic
compound have been constructed in a manner that only or mainly cancerous cells receive
treatment (8, 9). Implantable microelectromechanical systems (MEMS) are currently
being designed that can locally deliver anticancer agents to tumors at a controllable time,
rate, and dosage (10). The promising capabilities of these examples suggest that medical
devices may be the key to improving treatment delivery in cancer patients so that normal
cells are unharmed and adverse effects are either eliminated or reduced.
4Radiation Seeds
Several medical devices have arisen for cancer treatment that can deliver
radiation. Radiation seeds are extremely small medical devices (about 20-60
micrometers), usually spherical or rod-shaped, that contain radioactive material and can
be permanently injected into cancer patients (11). This type of internal radiation therapy
is called permanent brachytherapy (11). The seeds are injected into a specific area of the
body where they can highly localize near tumor cells and emit radiation. The emitted
radiation causes DNA damage of the tumor cells, and eventually apoptosis (11). SIR
spheres are radiation seeds that were approved by the FDA in 2002 as medical devices
for the treatment of liver cancer (11). They are resin microspheres that contain the
radioisotope Yttrium-90 and are delivered and embolized into the hepatic artery, which is
the main blood source of liver tumors, delivering close-range radiation directly to tumor
cells (12).  Pre-approval clinical trials showed that patients receiving SIR spheres
combined with chemotherapy had significantly higher survival rates than patients
receiving chemotherapy alone (29.4 months vs. 12.8 months) (13). Similar to SIR
spheres, Theraspheres are radiation seeds that are indicated for liver cancer treatment and
contain Yttrium-90; however, the microspheres are made out of glass rather than resin
(14). Other radiation seeds that contain the radioisotope Iodine-125 or Palladium-103
have been used to treat prostate cancer by injecting them directly into the prostate.
Radiation seeds remain inside the patient, but brachytherapy ceases after the radiation has
decayed (15). Long-term clinical trials testing these radiation seeds showed that disease-
free survival ranged from 66% to 87% of prostate cancer patients after an average of 10
5years (16). Radiation seeds offer several advantages over standard, external radiation
therapy that can not only lead to fewer normal cells being harmed, but also stronger doses
of radiation being delivered to the tumors.
Conventional radiation therapy involves exposing specific areas of the body of a
patient to external radiation to kill cancer cells within. However, many healthy, dividing
cells are also subjected to the radiation treatment, causing unsettling side effects. For
example, nausea and vomiting occur if the stomach or abdomen is exposed to the
radiation treatment and infertility can occur if the gonads are exposed.  In addition,
external radiation must bypass many layers of healthy tissue to reach the tumor cells,
minimizing the strength and effectiveness of the treatment (17). Radiation seeds can
solve these problems by providing internal treatment delivery rather than non-specific
external radiation. Radiation seeds are injected either directly into tumors or in areas that
would lead to selective tumor localization. Therefore, the majority of radiation is directed
towards tumor cells and many normal cells and tissues are avoided. For example, SIR
spheres and Theraspheres intend to evade damage to normal cells and side effects by
inserting the seeds into the hepatic artery. Since normal liver cells mainly receive blood
from portal circulation, and tumor cells from the hepatic artery, the overwhelming
majority of radiation should be delivered to tumor cells (12). Another advantage is that
the radiation does not have to bypass many layers of healthy tissue to reach the tumor.
This not only spares additional normal cells and tissues from receiving radiation, but also
strengthens the effects of radiation on tumor cells. After injection, the proximity of the
radiation seeds to the tumor allows for close-range, high-levels of radiation delivery.
Higher levels of radiation have stronger therapeutic results, so the tumor cells shrink or
6are eliminated more effectively. For example, clinical trials showed that Iodine-125 and
Palladium-103 radiation seeds provided significantly higher progression-free survival in
prostate cancer patients compared to conventional radiation therapy (18). In addition,
these radiation seeds showed a lower risk of adverse effects (18). Current research and
trials have tested permanent Cesium-131 radiation seeds for prostate cancer treatment.
Results of the clinical trials have shown that these radiation seeds combat highly
proliferative cells even better than Iodine-125 and Palladium-103 radiation seeds, with
similar safety (15). Therefore, radiation seeds can potentially have fewer side effects than
conventional radiation therapy and combat tumors more strongly as well. Furthermore, if
tumors can be eliminated more effectively, than fewer treatments, and consequently
fewer opportunities to harm normal cells, would be necessary to care for patients.
Clinical trials have illustrated the implications radiation seeds can have on not
only eliminating tumors, but preventing recurrence as well. Cancer recurrence is the
return of cancer after treatment noticeably eliminated all tumor cells in the body (19). In
one clinical trial, radiation seeds containing Phosphorous-32 were used to prevent
recurrence in liver cancer patients that had already undergone hepatectomy, partial
surgical removal of the liver. The results of the clinical trials demonstrated that
recurrence rates significantly decreased and overall survival at three years increased in
about 65 % of patients (20). In addition, after three years, no significant side effects were
observed that would normally occur from the systemic radioactive absorption associated
with conventional radiation therapy (20). These findings suggest that radiation seeds can
have significant implications in reducing the possibility of side effects. Since the
incidence of recurrence would require patients to undergo additional treatments, the
7chance that the normal cells of a patient would be affected by chemotherapy or radiation
also increases. This forces patients to endure more side effects or experience side effects
that were previously avoided. Therefore, by preventing recurrence, radiation seeds such
as Phosphorous-32 can greatly minimize the amount of side effects cancer patients
potentially experience. Implanting radiation seeds can possibly become a standard
procedure in cancer treatments that involve surgery. After tumors have been surgically
removed, radiation seeds can be implanted before ending the surgery to prevent
recurrence. Additionally, this would allow the radiation seeds to be positioned in the
exact locations desired by the oncologist, further diminishing the chances of side effects
from systemic radioactive absorption. The advantages of fewer side effects, more
effective tumor elimination, and recurrence prevention may lead to a future where
radiation seeds have replaced external radiation as the conventional radiation therapy for
cancer patients.
8Balloon Catheters
Other medical devices, such as balloon catheters, have also shown promise in
being able to diminish side effects by locally delivering radiation to tumors. Balloon
catheters are medical devices that comprise a tube with an inflatable balloon that can be
inserted into cavities or ducts within the body (21). The inflatable balloon allows the
desired region to be expanded to create space between the tissue and the substance being
delivered (21). In cancer treatment, balloon catheters are used as a form of temporary
brachytherapy. The balloon catheter is inserted into a cavity formed by surgical tumor
removal to release close-range radiation to tumor cells (21). After each daily treatment,
the catheter can be unplugged from the radiation source so that patients can carry out
normal activities (21). Once brachytherapy is completely finished, the balloon is deflated
and the catheter is removed (21). An example of a balloon catheter is the GliaSite
Radiation Therapy System (GliaSite RTS), which is approved for the treatment of brain
cancer. After a brain tumor has been surgically removed, the GliaSite RTS catheter is
inserted into the region and delivers liquid Iodine-125. After less than a week of
treatment, the catheter is completely removed (7). Another balloon catheter, the
MammoSite, received FDA approval in 2002 for breast cancer treatment (22). The
Mammosite is inserted into the cavity formed by tumor removal and delivers high-dose
radiation seeds. The radiation seeds are removed after each daily treatment and the
catheter is removed after the entire treatment is finished, which takes about five days
(22). Other balloon catheters have been used for breast cancer treatment as well, such as
SAVI and ClearPath (23). The localized delivery of balloon catheters offers several
9advantages over conventional radiation therapy, such as harming fewer normal cells and
decreasing treatment time for patients.
Similar to radiation seeds, since balloon catheters are inserted into a precise cavity
and the radiation is delivered internally, side effects can be significantly diminished
compared to conventional radiation therapy because fewer normal cells are exposed to
radiation. For example, after five years of observation, a clinical trial showed that
MammoSite treated patients as effectively as conventional radiation therapy and only
showed severe side effects (infection) in about 9 % of patients (24). Another advantage is
that balloon catheter treatment only takes a few days, while conventional radiation
therapy takes about six to seven weeks (21, 22). Since each additional day a patient is
exposed to radiation therapy is another opportunity that normal cells can be harmed,
fewer treatment days can potentially save patients from experiencing side effects.
Additionally, fewer treatment days improves patient quality of life by decreasing the time
and stress involved with constantly receiving cancer treatment. Balloon catheters may not
combat tumors as strongly as permanent radiation seeds, but they diminish the incidence
of adverse effects just as well. Furthermore, the temporary nature of balloon catheters
allows them to be used in regions that are not suitable for radiation seeds, such as the
brain (radiation seeds have not been proven safe and effective in the brain) (25). The
successful local deliverability of balloon catheters suggests that they can be used to
deliver other substances besides radiation, such as anticancer drugs, to tumor sites.
If balloon catheters are capable of delivering radiation and chemotherapy to
tumors, than the two main causes of cancer treatment side effects can be addressed. In
2009, the FDA gave market clearance to IsoFlow, a balloon catheter that can deliver
10
anticancer drugs (26). Just like with radiation, the catheter would be inserted into a region
that allows local delivery of the drug to tumor sites. This would avoid many of the
adverse effects that occur from the anticancer drug affecting normal cells (26). One can
understand how balloon catheters such as IsoFlow can immensely improve the safety and
efficacy of cancer treatments. For example, Avastin is an anticancer drug approved for
the treatment of several cancers. Avastin prevents angiogenesis, the formation of new
blood vessels. Angiogenesis is a common aspect of tumor cells and is necessary for their
growth (27). However, since Avastin is orally delivered and non-specific, problems can
arise in normal processes that involve the circulatory system. Patients receiving Avastin
can experience serious, fatal side effects such as bleeding, heart problems, wounds that
do not heal, and severe high blood pressure (27). In fact, the FDA has revoked the
approval of Avastin for breast cancer patients because the efficacy is not worth the risks
(28). If IsoFlow could be used to deliver Avastin, than treatment can be directly focused
on the tumor and many normal cells involved in blood circulation can be avoided. In
addition, the close-range delivery of Avastin to the tumor may increase the effectiveness
of the drug. Avastin is just one of many drugs that can possibly be improved by catheters
like IsoFlow. IsoFlow may benefit anticancer drugs that did not receive FDA approval
because of poor safety. If these drugs could be used with IsoFlow, than their safety may
be improved and the FDA may reconsider approval, bringing more anticancer drugs to
market and saving or prolonging numerous lives. Not only may balloon catheters join
radiation seeds as possible replacements for conventional radiation therapy, but the
ability to deliver drugs as well may make them the universal medical device for cancer
treatment. The promising future of devices like IsoFlow to minimize adverse effects and
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improve safety highlights the importance of other medical devices that can deliver
anticancer drugs, such as nanoparticles.
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Nanoparticles
In the medical field, nanoparticles are spherical medical devices, usually between
1-100 nanometers, that can be inserted into the body of a patient to provide a therapeutic
effect (29). Nanoparticles can be constructed out of several types of materials, but are
usually made of lipids or biodegradebale polymers (29). Lipids are naturally occurring
molecules that are present in cell membranes and polymers are large repeated molecules,
such as cellulose, that can be either natural or synthetic (30). In cancer treatment,
nanoparticles usually contain a therapeutic anticancer compound within the sphere, such
as a small molecule drug. The main purpose of nanoparticles is to deliver the drug that it
is carrying specifically to tumors and more efficiently than if the drug was administered
alone. Nanoparticles are spontaneously more inclined to target tumors because of the
enhanced permeability and retention effect (EPR effect). The EPR effect is a
characteristic of tumor cells that is caused by angiogenesis. When tumor cells undergo
angiogenesis, the new blood vessels are commonly leaky, and wider than preexisting,
normal blood vessels. This makes the blood vessels of the tumor more prone to absorbing
macromolecules, such as nanoparticles (31). If desired, the nanoparticles can be modified
to further increase the chances of tumor cells being targeted rather than normal cells. This
can be implemented several ways, such as by linking the exterior of the nanoparticle with
tumor-specific compounds, or by linking the nanoparticle with photactivation properties
so that the drug can only be activated in the presence of light. Nanoparticles release their
anticancer agent into tumor cells when they make contact and spontaneously fuse with
the tumor cell membrane (8). Although there are not any nanoparticle cancer treatments
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available in the U.S. today, several preclinical trials are currently showing exceptional
results, warranting their potential advantage in cancer treatment and fostering the
initiation of human clinical trials.
Preclinical trials have been illustrating how nanoparticles can significantly
decrease the incidence of adverse effects associated with standard chemotherapy. One
preclinical trial showed how polymer nanoparticles loaded with the anticancer drug
paclitaxel prevented lung tumor growth in over 70% of mouse models, without causing
any toxicity (32). These results demonstrate how nanoparticles can decrease side effects
by improving drug delivery because paclitaxel alone is known to cause hair loss, skin
irritation, weight loss, and other toxicities in mice. The paclitaxel-loaded nanoparticles
did not possess any tumor-specific properties, but local tumor delivery and the EPR effect
were enough to eliminate chemotherapy side effects (32). Various research has also been
conducted to test nanoparticles loaded with photosensitizers. Photosensitizers are
compounds that cause cell death, after they are activated by light, by triggering Reactive
Oxygen Species (ROS) formation (33). ROS are free radical products of oxygen
metabolism, which occurs in every cell. High levels of ROS result in DNA damage, cell
aging, and ultimately apoptosis in severe cases (34). After photosensitizers have been
inserted into a patient, light is only exposed at the area of the tumor. Therefore, regardless
of where photosensitizers are distributed throughout the body, only ones near the tumor
should be activated. This should spare many normal cells from being harmed by the ROS
damage. However, photosensitizers still cause side effects because of poor tumor
specificity and are thus limited as a cancer treatment option. Some side effects of
photosensitizers include skin burns and irritation, swelling, pain, and scarring (33). In one
14
preclinical trial, researchers attempted to specifically target tumor cells by placing
photosensitizers into lipid nanoparticles and counting on the EPR effect. Results of the
preclinical trial proved that the nanoparticles greatly decreased the side effects of
photosensitizers in mouse models. Mice that received the photosensitizers alone
experienced severe skin and liver damage four days after light activation, while mice that
received the photosensitizers within nanoparticles were unharmed (35). In addition, since
fewer photosensitizers were acting on normal cells and more were available to combat
cancer cells, the tumors were eliminated more effectively than the photosensitizers alone
(35). Therefore, by combining specific light exposure with a nanoparticle, photosensitizer
side effects can be significantly diminished. The various successes of nanoparticles in
preclinical trials have led to several candidates entering human clinical trials. For
example, the nanoparticle Myocet has just begun Phase III trials in the United States for
the treatment of breast cancer, and the nanoparticles SGT-53 (SynerGene Therapeutics-
53) and INGN-401 (Introgen Therapeutics-401) are just starting Phase I trials for the
treatment of lung cancer and solid tumors, respectively (36). Studies have demonstrated
that the specificity of nanoparticles can decrease the side effects of small molecules;
however, if there was a way nanoparticles could also improve the specificity of larger
molecules, such as antibodies, than a truly effective approach to cancer treatment may
arise.
Similar to photosensitizers, photoactivated compounds have been studied for use
within nanoparticles. Researchers have hypothesized constructing nanoparticles that can
start producing proteins within the body after photoactivation (37). These nanoparticles
are made of lipids and contain all the machinery required for protein synthesis (amino
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acids, DNA, ribosomes, etc.) inside the sphere. However, the DNA within the
nanoparticle is bound to a photo-labile group, called DMNPE, (4,5-dimethoxy-2-
nitrophenyl diazoethane) that prevents protein production until photoactivation (37). Just
like with photosensitizers, light will only be exposed in the desired region of the body.
This methodology was proven in mice when Green Fluorescent Protein was produced
after light activation (37). This approach can be extremely advantageous in directly
delivering large molecules that either cannot fit into particular nanoparticles in their final
state or are usually quickly broken down by the body. For example, antibodies are large
molecules that have made an incremental impact on cancer treatment, but some are
plagued by serious side effects. Herceptin is an antibody used to treat breast cancer.
Herceptin binds to the cellular receptor Her2, which is overexpressed in many breast
cancers, and inhibits its activity (38). However, one of the most severe and troubling side
effects of Herceptin is heart damage. This is caused because heart cells also possess the
Her2 receptor. Therefore, Herceptin is probably binding to heart cells and inhibiting their
normal function (39). If Herceptin can specifically target the Her2 receptors of breast
tumor cells, the incidence of heart damage can be decreased. This specificity can possibly
be obtained by incorporating the machinery required to produce Herceptin (with the DNA
bound to a photo-labile group) within a nanoparticle. Once introduced into the patient,
light will only be exposed to the areas of the breast that possess tumor cells. As a result,
Herceptin should only be produced in these regions and heart cells should not be affected.
This approach can possibly be used with other antibodies as well, such as Avastin, and
illustrates the vast implications nanoparticles can have on the future of cancer treatment
by providing specific delivery to various therapeutic agents.
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Carbon Nanotubes
Similar to nanoparticles, carbon nanotubes (CNTs) are able to carry anticancer
agents to tumors; however, they possess additional properties that make them unique
medical devices. CNTs are biodegradable, hollow tubes made of carbon that have a
diameter of about .4 to 100 nanometers (40). Anticancer agents can either be loaded
within the CNTs or linked to the outside of the tubes. Once inserted into the body, CNTs
enter cells by either passive diffusion or endocytosis, cellular uptake (40). Similar to
nanoparticles, CNTs favor tumor cells because of the EPR effect, and tumor-specific
compounds can be linked to the outside of the CNTs to guide them directly to tumor cells
(40). Once inside the cell, there are several ways the drug can be released from the CNTs.
If the therapeutic agent was linked to the outside of the CNTs, a linker would be used that
is cleaved within the cytoplasm. Therefore, as soon as the CNTs enter a cell, the linker
would be cut and the drug will be released (40). If the drug was loaded within the CNTs,
the open ends would be sealed with molecules that can also be cleaved once they enter
the cytoplasm (40). A concern that has hindered the success of CNTs, and nanoparticles,
in clinical trials is that they can be harmful to any normal cells they enter (40). As a
result, researchers have focused strongly on providing these devices with tumor-
specificity as previously mentioned. Another advantage of CNTs is that their chemical
structure allows them to act as heat conductors for thermal ablation (40). Thermal
ablation is a method to eliminate tumors by inserting heat-generating materials into the
cancer cells. Once a cell is heated above 55°C, the cell dies because of protein
denaturation (40). Studies have shown that CNTs within cells can be heated by exposing
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them to radiofrequency or near infrared wavelengths (40). These wavelengths would only
be exposed in areas that possess tumor cells. Therefore, predominately tumor cells, and
hardly any normal cells, will be destroyed because only tumor cells should both contain
the CNTs and be exposed to the wavelength (40). CNT technology for cancer treatment is
fairly new, so the majority of CNT optimism has been generated from animal studies and
preclinical trials.
Studies have shown how CNTs can improve tumor-specificity of various
anticancer drugs. Similar to nanoparticles, CNTs were used with the drug paclitaxel to
see if side effects would be diminished. Results showed that CNTs linked with paclitaxel
on the exterior of the tube did not cause any side effects in mouse models, and that tumor
cells were eliminated more efficiently than paclitaxel alone (70% of tumor cells
eliminated vs. 3%) (9). Several other studies showed that linking CNTs with folic acid
derivatives greatly increased tumor-specificity of the anticancer drugs they were carrying
(41). This approach was successful because tumor cells are known to overexpress folic
acid receptors (41). Considering the link between tumor-specificity and diminished side
effects, these findings are highly influential. Other studies have shown the advantage
CNTs have in thermal ablation therapy. Without the use of CNTs, thermal ablation has
been an ineffective treatment. Usually heat-conducting electrodes are inserted into tumors
and exposed to radiofrequency or near infrared wavelengths. However, the electrodes
deliver heat to many healthy cells surrounding and distant from the tumor cells. This
causes side effects such as nausea, vomiting, fatigue, hair loss, skin irritation, acid reflux,
and lack of salivary function (9). On the other hand, results of trials using CNTs showed
complete elimination of tumor cells in rabbits after being exposed to radiofrequency
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without any adverse effects (42). This highlights how CNTs can diminish side effects by
improving treatment delivery. CNTs were able to seclude the delivery of lethal thermal
energy to tumor cells, keeping normal cells healthy. The various findings illustrate that
CNTs possess the same drug-carrying capabilities as nanoparticles with additional
treatment benefits such as thermal ablation. If CNTs can combine chemotherapy and
thermal ablation into a single treatment, than a convenient, powerful approach to
attacking tumors would be generated.
Individually, chemotherapy and thermal ablation have limitations in certain
instances. For example, one problem with chemotherapy is the occurrence of resistance.
In some cases, such as the anticancer drug doxorubicin, a previously effective treatment
does not work as well because some of the tumor cells develop resistances against the
drug (43). This forces patients to undergo additional treatments to eliminate the
remaining cancer cells, causing patients to experience more side effects. If one is
concerned about resistance, than thermal ablation may be the appropriate treatment
option; however, a limitation of thermal ablation is that it cannot be used if the tumor is
larger than 5 cm (44). CNTs may be the answer to treating resistant tumors that are larger
than 5 cm by simultaneously using chemotherapy and thermal ablation. The CNTs can be
loaded with the anticancer drug and injected into the patient. Once the oncologist believes
the drug has been delivered into the tumor cells and has completed its therapeutic effect,
a radiofrequency or near infrared wavelength can be exposed at the tumor site to
eliminate any tumor cells that were resistant to the anticancer drug. Therefore,
chemotherapy can overcome the size limitations of thermal ablation and thermal ablation
can remove the resistant cells that survived chemotherapy. Furthermore, this approach
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can fight cancer more effectively by eliminating more tumor cells and avoids the side
effects of the further treatments needed to treat the resistant cells. The unique properties
of CNTs make them a versatile medical device that can diminish cancer patient side
effects through several methods.
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Microelectromechanical Systems
Other medical devices whose unique properties allow them to have substantial
implications on cancer treatment are microelectromechanical systems (MEMS). MEMS
are medical devices that basically act as small machines (about .02 to 1 millimeter) (10).
In cancer treatment, a MEMS device would be implanted into the patient near the tumor
site. The MEMS device would possess a reservoir that contains the desired drug, and a
rechargeable battery (10). A tube would connect the drug reservoir to a region highly
proximal to the tumor. The amount, rate, and time of drug release and battery recharging
would be wirelessly controlled by an oncologist during each treatment visit (10). Once
treatment is completely finished, the MEMS device can be safely removed by surgery
(10). Another advantage of MEMS devices is that one device can contain several
different drugs, each within a different reservoir.  The release of each drug would be
individually controlled by the oncologist (45). Co-administration of multiple drugs is a
common theme in cancer treatment when a single drug is ineffective on its own (46).
Although there are not any MEMS devices that have been tested in human patients today
for delivering anticancer compounds, several have been constructed and implanted into
animal models (45, 47).
One animal study demonstrated how a MEMS device could improve the drug
delivery of an anticancer drug used to combat brain tumors. Brain cancers are usually
difficult to treat because of the blood-brain-barrier. Since anticancer drugs are mostly
orally delivered, they must bypass the blood-brain-barrier to reach the brain tumor cells.
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However, the blood-brain-barrier is difficult to penetrate and even some of the best brain
cancer drugs have difficulty getting to the brain. As a result, more drug molecules are
available to harm normal cells outside the brain (47). For example, temozolomide is a
brain cancer drug whose affect on normal cells causes side effects such as difficulty
walking or coordinating movement, confusion, anxiety, seizures, infection, urinary
incontinence, and several others (48). Researchers designed a MEMS device that can be
implanted within the skull and locally deliver temozolomide to brain tumor cells. Results
showed that the most efficient MEMS device significantly increased the survival of rats
with brain cancer (47). About 43% of the rats survived for the entire study period (120
days) and the median survival was 40 days (47). Implanting the MEMS within the skull
increased treatment efficiency because the blood-brain-barrier was avoided and more
temozolomide was able to directly act on brain tumor cells. In addition, the side effects
that are caused by temozolomide being outside of the brain would theoretically be
avoided. Another study utilized a MEMS device to exploit the advantages of siRNA (49).
SiRNA (small interfering RNA) is an RNA molecule that can silence the expression of a
gene with the complementary nucleotide sequence (50). One of the limitations of siRNA
is that they can be easily degraded in the body by enzymes (50). An encasing structure,
such as a MEMS device, is required to protect the siRNA from enzymatic degradation so
that it can be safely delivered to tumors. In this study, a MEMS device was able to
directly deliver siRNA that silences the gene expressing SPK-1, a radioresistant protein
found in tumor cells (49). Radioresistant proteins help tumor cells survive radiation,
pressuring oncologists to administer higher doses. However, there is a limit to the amount
of radiation exposure a patient can receive in a lifetime before it becomes severely
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damaging or fatal (51). Therefore, being able to use lower doses of radiation has always
been desired so that fewer normal cells are damaged and the maximum capacity of
radiation exposure is less likely to be reached. The researchers intended on using the
siRNA to make the tumor cells more sensitive to radiation therapy. Testing the device in
mice demonstrated that tumors regressed over 50% after MEMS siRNA delivery and
radiation therapy (49). Therefore, the increased vulnerability of tumor cells means a
lower dosage of radiation can potentially be used, decreasing the amount of normal cells
harmed. The MEMS device improved the delivery of siRNA so that the side effects of
radiation therapy could be diminished.  As technology improves and MEMS devices
become optimized, the number of cancers that can possibly be treated and drugs that can
be delivered should amplify.
A limitation of MEMS devices is that the requirement of a battery increases the
size of the device. In some cases, the large size of the MEMS device prevents it from
being used to treat some cancers because of unsuitable implantation areas. However, one
study demonstrated the success of a battery-less MEMS device (52). Rather than using a
battery, the drug is released after applying a magnetic field, which removes a magnetic
seal that is blocking the drug. Results showed that the device successfully delivered the
anti-proliferative drug docetaxel (52). Although this study was mainly intended for
treating proliferative retinopathy, one can understand the potential of this device for
treating proliferative cells in cancer. Perhaps other methods can be considered for
activating drug releases, such as light activation, similar to releasing drugs in
nanoparticles. Since a battery-less MEMS device would possibly increase the amount of
cancers that can be treated, more patients would be able to avoid the side effects of taking
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their anticancer drug alone. However, a limitation that has deterred the clinical progress
of MEMS devices is that they can be damaged by moisture or external conditions within
the body of a patient (10). The methods required to protect the device usually limit its
functionality (10). Therefore, device design must be optimized so that the MEMS device
is simultaneously protected and effective. The quick advancement of modern technology
supports the hope that MEMS devices will be clinically successful. Similar to the
previous medical devices discussed, MEMS devices can diminish the side effects of




Medical devices can perform a wide variety of functions that can be used in the
medical field. One of the many areas where medical devices can provide assistance is in
treatment delivery. This is especially important in cancer treatment because poor
treatment delivery is known to result in adverse effects in patients. These adverse effects
not only endanger the well-being of a patient, but also hinder the application of potential
or existing cancer treatments. Side effects are mainly a result of the treatment not being
specific or directed towards tumor cells. Medical devices such as radiation seeds and
balloon catheters have shown to deliver radiation without causing many of the side
effects associated with conventional radiation therapy. Loadable medical devices such as
nanoparticles, carbon nanotubes, and MEMS devices have demonstrated that specifically
and/or locally carrying drugs to tumor sites significantly diminishes side effects
compared to using the drug alone. By enhancing safety, this can improve existing drugs,
increasing treatment options for cancer patients, and can magnify the probability of FDA
approval of future drugs. The construction of these devices fosters interest in the
capabilities of future devices that are intended to improve treatment delivery. One can
imagine that the nano-sized robots that are commonly discussed in movies would be the
ideal medical devices for treatment delivery. Researchers have hypothesized that these
nanobots, or pharmacytes, can possibly be constructed (53). The pharmacytes would be
mini robots that are about the same size as nanoparticles, but would be self-powered and
wirelessly controlled like MEMS devices. The pharmacytes would be able to carry
therapeutic agents directly to tumors, without ever harming normal cells (53).
25
Understanding that these characteristics of size, wireless control, and drug carrying
ability have already been obtained in current medical devices, pharmacytes may actually
become a reality. Nevertheless, the various examples and results illustrate how medical
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